|
[Related PubMed/MEDLINE]
Total Number of Papers: 2171
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: CCA |
| Long Form |
: cholangiocarcinoma |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
13‑cis‑retinoic acid inhibits the self‑renewal, migration, invasion and adhesion of cholangiocarcinoma cells. |
--- |
| 2 |
2023 |
A phase II study of nab-paclitaxel and gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy (NACHO). |
DCR, ORR, OS, PFS, TRAEs |
| 3 |
2023 |
Advanced endoscopy meets molecular diagnosis of cholangiocarcinoma. |
--- |
| 4 |
2023 |
Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review. |
--- |
| 5 |
2023 |
ARHGAP21 Is Involved in the Carcinogenic Mechanism of Cholangiocarcinoma: A Study Based on Bioinformatic Analyses and Experimental Validation. |
CCK8, GO, GSEA, KEGG, RhoGAP |
| 6 |
2023 |
Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy. |
--- |
| 7 |
2023 |
Combined Inhibition of Smoothened and the DNA Damage Checkpoint WEE1 Exerts Antitumor Activity in Cholangiocarcinoma. |
Hh, iCCA, PTCH1, Smo, TFs |
| 8 |
2023 |
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. |
--- |
| 9 |
2023 |
Curcumin analog WZ26 induces ROS and cell death via inhibition of STAT3 in cholangiocarcinoma. |
NAC, ROS, STAT3 |
| 10 |
2023 |
Development and validation of a nomogram to predict cancer-specific survival with unresected cholangiocarcinoma undergoing external radiotherapy. |
C-index, CSS, DCA, SEER |
| 11 |
2023 |
Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy. |
FGFR, IDH |
| 12 |
2023 |
Diagnosis of Cholangiocarcinoma. |
ERCP, EUS |
| 13 |
2023 |
Distinct cholangiocarcinoma cell migration in 2D monolayer and 3D spheroid culture based on galectin-3 expression and localization. |
--- |
| 14 |
2023 |
Effects of Health Literacy Promotion Programs for Preventing Opisthorchiasis and Cholangiocarcinoma: a Systematic Review and Meta-analysis. |
OV |
| 15 |
2023 |
Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report and Literature Review of 890 Patients Affected by Uncommon Primary Liver Tumor Presentation. |
BDTT, HBV, HCC, RFA |
| 16 |
2023 |
High Level of Serum Coiled-coil Domain Containing 25 (CCDC25) as a Diagnostic Marker for Cholangiocarcinoma But Not for Other Cancers. |
BC, CCDC25, CRC, GEPIA2, HC, HCC, HPA |
| 17 |
2023 |
Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. |
CAF, FRGs |
| 18 |
2023 |
Identification of therapeutic targets and prognostic biomarkers in cholangiocarcinoma via WGCNA. |
DEGs, OS, WGCNA |
| 19 |
2023 |
Imaging Features of Main Hepatic Resections: The Radiologist Challenging. |
CT, FLT, HCC, MRI, US |
| 20 |
2023 |
Impact of metformin on the incidence of human cholangiocarcinoma in diabetic patients: a systematic review and meta-analysis. |
CI, RR |
| 21 |
2023 |
L-Fucose inhibits the progression of cholangiocarcinoma by causing microRNA-200b overexpression. |
FITC/PI, HUVECs, MAPK7, miR-200b |
| 22 |
2023 |
Loss of tumor suppressor menin expression in high grade cholangiocarcinomas. |
IHC, TMA |
| 23 |
2023 |
MC-GAT: multi-layer collaborative generative adversarial transformer for cholangiocarcinoma classification from hyperspectral pathological images. |
CNN, ViT |
| 24 |
2023 |
Metabolic reprogramming and its clinical implication for liver cancer (HEP-22-1008). |
HCC, NAFLD |
| 25 |
2023 |
Metabolic reprogramming and its clinical implication for liver cancer. |
HCC, NAFLD |
| 26 |
2023 |
Microalga Chlorella sp. extract induced apoptotic cell death of cholangiocarcinoma via AKT/mTOR signaling pathway. |
--- |
| 27 |
2023 |
Modelling metastatic colonization of cholangiocarcinoma organoids in decellularized lung and lymph nodes. |
CCAOs, ECM |
| 28 |
2023 |
Mutational Impacts on the N and C Terminal Domains of the MUC5B Protein: A Transcriptomics and Structural Biology Study. |
MD |
| 29 |
2023 |
Neoadjuvant Chemotherapy for Intrahepatic, Perihilar, and Distal Cholangiocarcinoma: a National Population-Based Comparative Cohort Study. |
AC, NAC, NCDB, OS, SA |
| 30 |
2023 |
Overexpression of Insulin Receptor Substrate 1 (IRS1) Relates to Poor Prognosis and Promotes Proliferation, Stemness, Migration, and Oxidative Stress Resistance in Cholangiocarcinoma. |
IHC, IRS-1 |
| 31 |
2023 |
Pathology of Cholangiocarcinomas. |
iCCA |
| 32 |
2023 |
Plasmon-Enhanced Single Extracellular Vesicle Analysis for Cholangiocarcinoma Diagnosis. |
FLEX, tEVs |
| 33 |
2023 |
Primary Liver Cancers: Connecting the Dots of Cellular Studies and Epidemiology with Metabolomics. |
HB, HCC |
| 34 |
2023 |
Racial Segregation Among Patients with Cholangiocarcinoma-Impact on Diagnosis, Treatment, and Outcomes. |
CI, CSS, IoD, RR |
| 35 |
2023 |
Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma. |
GC, HCC, ICI, MVI, SBRT, TACE, TARE, TKIs |
| 36 |
2023 |
Study of the association between a MICA gene polymorphism and cholangiocarcinoma in Egyptian patients. |
NKG2D, NKG2DLs |
| 37 |
2023 |
Survival analysis of extrahepatic cholangiocarcinoma based on surveillance, epidemiology, and end results database. |
CI, eCCA, LN, SEER |
| 38 |
2023 |
Tumor decellularization reveals proteomic and mechanical characteristics of the extracellular matrix of primary liver cancer. |
ECM, HCC |
| 39 |
2023 |
Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies. |
HCC, HPB, IO, PDA, TRM |
| 40 |
2023 |
Tumor ratio of unsaturated to saturated sulfatide species is associated with disease-free survival in intrahepatic cholangiocarcinoma. |
iCCA |
| 41 |
2022 |
3D Silk Fibroin-Gelatin/Hyaluronic Acid/Heparan Sulfate Scaffold Enhances Expression of Stemness and EMT Markers in Cholangiocarcinoma. |
CSC, ECM, EMT, SF, SF-GHHs |
| 42 |
2022 |
A Case Report of CHEK2 and MUTYH Germline Mutations Associated With Cholangiocarcinoma in a Young Patient. |
--- |
| 43 |
2022 |
A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls. |
CEUS, CT, HCC, MRI |
| 44 |
2022 |
A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO). |
DCR, OS, PFS, SBRT, TRR |
| 45 |
2022 |
Aberrantly methylated-differentially expressed genes and related pathways in cholangiocarcinoma. |
GEO, Hyper-LGs, Hypo-HGs |
| 46 |
2022 |
Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells. |
--- |
| 47 |
2022 |
Activation of the Unfolded Protein Response (UPR) Is Associated with Cholangiocellular Injury, Fibrosis and Carcinogenesis in an Experimental Model of Fibropolycystic Liver Disease. |
alpha-SMA, TAA, TM, UPR |
| 48 |
2022 |
Advances in Targeted Immunotherapy for Hepatobiliary Cancers. |
BTC, GBC, HCC |
| 49 |
2022 |
Advances of cancer-associated fibroblasts in liver cancer. |
CAFs, HCC, TME |
| 50 |
2022 |
Albendazole-induced autophagy blockade contributes to elevated apoptosis in cholangiocarcinoma cells through AMPK/mTOR activation. |
3-MA, ABZ, CQ |
| 51 |
2022 |
All-trans-retinoic acid induces RARB-dependent apoptosis via ROS induction and enhances cisplatin sensitivity by NRF2 downregulation in cholangiocarcinoma cells. |
ATRA, RAR, ROS |
| 52 |
2022 |
An Immunity-Related Gene Model Predicts Prognosis in Cholangiocarcinoma. |
8-IRDEGs, GEO, ImmPort, LASSO, RFS, TIDE, TIS |
| 53 |
2022 |
An Innovative Test for the Rapid Detection of Specific IgG Antibodies in Human Whole-Blood for the Diagnosis of Opisthorchis viverrini Infection. |
ICT, WBS |
| 54 |
2022 |
An Insight into Cholangiocarcinoma and Recent Advances in its Treatment. |
--- |
| 55 |
2022 |
An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. |
CAR-T, HCC |
| 56 |
2022 |
Annexin A1 Is a Potential Prognostic Marker for, and Enhances the Metastasis of, Cholangiocarcinoma. |
ANXA1, IHC |
| 57 |
2022 |
Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2alpha, and HIF-1alpha. |
CK2 |
| 58 |
2022 |
Anti-metastatic Potential of Natural Triterpenoid Cucurbitacin B Against Cholangiocarcinoma Cells by Targeting Src Protein. |
--- |
| 59 |
2022 |
Antibiotic-Resistant Bacteria Colonizing the Bile Duct Are Associated with Increased Morbidity and Mortality after Resection of Extrahepatic Cholangiocarcinoma. |
ASA, CHD, CI, OR |
| 60 |
2022 |
Antitumor activity of T cells secreting alphaCD133-alphaCD3 bispecific T-cell engager against cholangiocarcinoma. |
alphaCD133-alphaCD3-ENG |
| 61 |
2022 |
Antitumor Effects of Delta (9)-Tetrahydrocannabinol and Cannabinol on Cholangiocarcinoma Cells and Xenograft Mouse Models. |
CBN |
| 62 |
2022 |
Apoptotic and Anti-metastatic Effects of Atractylodes lancea (Thunb.) DC. in a Hamster Model of Cholangiocarcinoma. |
AL, OV/DMN |
| 63 |
2022 |
Application of Urine and Copro Antigen Assays after Primary Infection and Drug Treatment in an Experimental Opisthorchiasis Animal Model. |
--- |
| 64 |
2022 |
Arsenic-contaminated drinking water and cholangiocarcinoma. |
ECC, ICC |
| 65 |
2022 |
Artificial intelligence and cholangiocarcinoma: Updates and prospects. |
AI |
| 66 |
2022 |
Association between Metabolic Disorders and Cholangiocarcinoma: Impact of a Postulated Risk Factor with Rising Incidence. |
--- |
| 67 |
2022 |
Associations between ultrasound screening findings and cholangiocarcinoma diagnosis in an at-risk population. |
aOR, CI, DBD, LM, US |
| 68 |
2022 |
Associations of Racial and Ethnic Category, Age, Comorbidities, and Socioeconomic Factors on Concordance to NCCN Guidelines for Patients With High-Risk Biliary Tract Cancers After Surgery. |
BTC, CT, NCDB, RT |
| 69 |
2022 |
Bile detection of squamous cell carcinoma antigen (SCCA) in extrahepatic cholangiocarcinoma. |
SCCA, SCCA1 |
| 70 |
2022 |
Bile-derived exosome noncoding RNAs as potential diagnostic and prognostic biomarkers for cholangiocarcinoma. |
ncRNA |
| 71 |
2022 |
Biliverdin reductase B impairs cholangiocarcinoma cell motility by inhibiting the Notch/Snail signaling pathway. |
BLVRB, EMT |
| 72 |
2022 |
Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know. |
HCC |
| 73 |
2022 |
Blockade of chloride channel-3 enhances cisplatin sensitivity of cholangiocarcinoma cells though inhibiting autophagy. |
ClC-3 |
| 74 |
2022 |
Blockade of GRP78 Translocation to the Cell Surface by HDAC6 Inhibition Suppresses Proliferation of Cholangiocarcinoma Cells. |
GRP78 |
| 75 |
2022 |
BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner. |
--- |
| 76 |
2022 |
Cancer-Associated Fibroblasts in Cholangiocarcinoma: Current Knowledge and Possible Implications for Therapy. |
alpha-SMA, CAFs |
| 77 |
2022 |
Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways. |
CBD, CBG |
| 78 |
2022 |
Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. |
PD-1 |
| 79 |
2022 |
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers. |
CPEs, HCC, MORV, VSV |
| 80 |
2022 |
Characterization of the Estrogen Response Helps to Predict Prognosis and Identify Potential Therapeutic Targets in Cholangiocarcinoma. |
ESRS |
| 81 |
2022 |
Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles. |
--- |
| 82 |
2022 |
Chidamide Suppresses the Growth of Cholangiocarcinoma by Inhibiting HDAC3 and Promoting FOXO1 Acetylation. |
CDM, HDACs |
| 83 |
2022 |
Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. |
DNA vaccine, iCCA, PET, TAA |
| 84 |
2022 |
Cholangiocarcinoma Attributed to Occupation: A Systematic Reviews. |
--- |
| 85 |
2022 |
Cholangiocarcinoma cell proliferation is enhanced in primary sclerosing cholangitis: A role for IL-17A. |
CCAOs, IL, PSC |
| 86 |
2022 |
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. |
ICD-11, LAD, MD, mOS |
| 87 |
2022 |
Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids. |
FA, FAO, NHC, Nicd1 |
| 88 |
2022 |
Cholangiocarcinoma protective factors in Greater Mekong Subregion: Critical issues for joint planning to sustainably solve regional public health problems. |
GMS, OV |
| 89 |
2022 |
Cholangiocarcinoma: a review of the literature and future directions in therapy. |
EGFR, FGFR, IDH1 |
| 90 |
2022 |
Cholangiocarcinoma: the role of genetic and epigenetic factors; current and prospective treatment with checkpoint inhibitors and immunotherapy. |
--- |
| 91 |
2022 |
Chromosomal aberrations, visualized using UroVysion fluorescence in-situ hybridization assay, can predict poor prognosis in formalin-fixed paraffin-embedded tissues of cholangiocarcinoma patients. |
FFPE, FISH, OS |
| 92 |
2022 |
CHST4 might promote the malignancy of cholangiocarcinoma. |
DEGs, PPI, qPCR, STRING |
| 93 |
2022 |
CircSETD3 (hsa_circ_0000567) inhibits proliferation and induces apoptosis in cholangiocarcinoma cells via downregulation of microRNA-421 expression. |
Bax, Bcl-2, BMF, circRNAs, miR, qRT-PCR |
| 94 |
2022 |
Circular RNAs in cholangiocarcinoma. |
ceRNA, circRNAs, RBPs |
| 95 |
2022 |
Circulating Bile Acids as Biomarkers for Disease Diagnosis and Prevention. |
AD, BAs, HCC, IR, NAFLD, T2DM |
| 96 |
2022 |
Circulating messenger RNA variants as a potential biomarker for surveillance of hepatocellular carcinoma. |
EV, HCC, mRNA, SNPs |
| 97 |
2022 |
Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma. |
CSS, CTC, GBCA, RC |
| 98 |
2022 |
Circ_0000591 served as endogenous RNA for miR-326 to promote progression of cholangiocarcinoma via the TLR4/MyD88/IL6 axis. |
circRNAs, HCC |
| 99 |
2022 |
Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. |
ACRT, dCRT, nCRT |
| 100 |
2022 |
Clinical Practice of Targeted Capture Sequencing to Identify Actionable Alterations in Cholangiocarcinoma. |
--- |
|
A Search Service for Abbreviation / Long Form
